Core Viewpoint - Polyrizon Ltd. has filed a divisional patent application for its Trap & Target (T&T) platform technology, aimed at enhancing intranasal drug delivery and improving medication effectiveness [1][2]. Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels, specifically designed to create a barrier against viruses and allergens while delivering medications effectively [8]. Patent Application Details - The divisional patent application is specifically for the T&T platform, which is part of a broader strategy to secure intellectual property for its two core technologies: Capture and Contain (C&C) and Trap and Target (T&T) [1][5]. - The T&T platform aims to improve the bioavailability of active pharmaceutical ingredients (APIs) and address challenges in local and systemic drug delivery [2]. Key Features of the T&T Platform - Prolonged Residence Time: Enhances the duration drugs remain at the nasal absorption site for better absorption and efficacy [7]. - Improved Bioavailability: Increases the amount of drug reaching systemic circulation, potentially improving therapeutic outcomes [7]. - Controlled Release: Allows for precise management of API release kinetics [7]. - Prevention of Dripping: Designed to prevent formulation from dripping out of the nasal cavity [7]. - Biodegradable Components: Utilizes safe and environmentally friendly biodegradable polymers [7]. - Versatility: Compatible with various drug types, including small molecules, proteins, peptides, and antibodies [7]. CEO Commentary - The CEO of Polyrizon emphasized that the patent application is a significant step in strengthening the company's global intellectual property portfolio and believes the T&T platform can transform intranasal drug delivery, improving efficacy and safety for a range of medications [4].
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform